Rocket Pharmaceuticals Inc., RCKT, FDA Calendar, PDUFA Date

Company Name	Rocket Pharmaceuticals, Inc. RCKT
Drug Name	KRESLADI (Resubmitted BLA)
Event Name	FDA decision on KRESLADI for the treatment of for severe Leukocyte Adhesion Deficiency-I
Event Date	03/28/2026
Outcome Date	03/27/2026
Outcome	FDA Approves KRESLADI for pediatric patients with severe Leukocyte Adhesion Deficiency-I (LAD-I) on Mar 27, 2026
Drug Status	The FDA declined to approve KRESLADI in June 2024, requesting limited additional Chemistry Manufacturing and Controls (CMC) information to complete its review.
Rival Drugs
Market Potential
Other Approvals
News

Return to FDA Calendar

RELATED NEWS (Rocket Pharmaceuticals, Inc.)

Slide Shows